Testosterone replacement therapy does not promote priapism in hypogonadal men with sickle cell disease: 12-month safety report

Andrology

Volumn 1, Issue 4, 2013, Pages 576-582

  Morrison, B F ^a   Reid, M ^a   Madden, W ^a   Burnett, A L ^b  

^a UNIVERSITY OF THE WEST INDIES   (Jamaica)

^b DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

Erectile dysfunction; Hypogonadism; Nebido; Nitric oxide; Testosterone undecanoate

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; BILIRUBIN; CREATININE; GLUCOSE; HEMOGLOBIN; LACTATE DEHYDROGENASE; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE; TESTOSTERONE UNDECANOATE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANDROGEN DEFICIENCY IN THE AGEING MALE; ANDROGEN THERAPY; ARTICLE; AZOOSPERMIA; BILIRUBIN BLOOD LEVEL; BREAST DISEASE; BREAST SWELLING; CARDIOVASCULAR SYMPTOM; CLINICAL ARTICLE; COHORT ANALYSIS; DISEASE ASSOCIATION; DRUG HYPERSENSITIVITY; DRUG SAFETY; EDEMA; FOLLOW UP; GLUCOSE BLOOD LEVEL; HEMATOCRIT; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGONADISM; INFERTILITY; INJECTION SITE PAIN; INTERNATIONAL INDEX OF ERECTILE FUNCTION; KIDNEY FUNCTION TEST; LACTATE DEHYDROGENASE BLOOD LEVEL; LEG SWELLING; LIVER FUNCTION TEST; MALE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; OPEN STUDY; PHASE 1 CLINICAL TRIAL; PILOT STUDY; PRIAPISM; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QUALITY OF LIFE; QUESTIONNAIRE; SEMEN ABNORMALITY; SEXUAL FUNCTION; SEXUAL SATISFACTION; SICKLE CELL ANEMIA; TESTOSTERONE BLOOD LEVEL; TREATMENT DURATION; WORLD HEALTH ORGANIZATION QUALITY OF LIFE;

ADULT; ANEMIA, SICKLE CELL; BIOLOGICAL MARKERS; GENETIC PREDISPOSITION TO DISEASE; HEMOGLOBIN, SICKLE; HOMOZYGOTE; HORMONE REPLACEMENT THERAPY; HUMANS; HYPOGONADISM; INJECTIONS, INTRAMUSCULAR; JAMAICA; MALE; PENILE ERECTION; PILOT PROJECTS; PRIAPISM; QUESTIONNAIRES; RISK FACTORS; TESTOSTERONE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84879480328     PISSN: 20472919     EISSN: 20472927     Source Type: Journal    
DOI: 10.1111/j.2047-2927.2013.00084.x     Document Type: Article

References (49)

1. Abbasi AA, Prasad AS, Ortega J, Congco E & Oberleas D. (1976) Gonadal function abnormalities in sickle cell anemia. Studies in adult male patients. Ann Intern Med 85, 601-605.
2. Araujo AB, O'Donnell AB, Brambilla DJ, Simpson WB, Longcope C, Matsumoto AM et al. (2004) Prevalence and incidence of androgen deficiency in middle-aged and older men: estimates from the Massachusetts Male Aging Study. J Clin Endocrinol Metab 89, 5920-5926.
3. Asnani MR, Lipps GE & Reid ME. (2009) Utility of WHOQOL-BREF in measuring quality of life in sickle cell disease. Health Qual Life Outcomes 7, 75.
4. Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS et al. (2010) Testosterone therapy in men with androgen deficiency syndromes: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 95, 2536-2559.
5. Bhasin S, Pencina M, Jasuja GK, Travison TG, Coviello A, Orwoll E et al. (2011) Reference ranges for testosterone in men generated using liquid chromatography tandem mass spectrometry in a community-based sample of healthy nonobese young men in the Framingham Heart Study and applied to three geographically distinct cohorts. J Clin Endocrinol Metab 96, 2430-2439.
6. Bivalacqua TJ, Liu T, Musicki B, Champion HC & Burnett AL. (2007) Endothelial nitric oxide synthase keeps erection regulatory function balance in the penis. Eur Urol 51, 1732-1740.
7. Bivalacqua TJ, Musicki B, Kutlu O & Burnett AL. (2012) New insights into the pathophysiology of sickle cell disease-associated priapism. J Sex Med 9, 79-87.
8. Burnett AL. (2006) Nitric oxide in the penis-science and therapeutic implications from erectile dysfunction to priapism. J Sex Med 3, 578-582.
9. Burnett AL & Bivalacqua TJ. (2007) Priapism: current principles and practice. Urol Clin North Am 34, 631-642, viii.
10. Burnett AL, Musicki B, Jin L & Bivalacqua TJ. (2006) Nitric oxide/redox-based signalling as a therapeutic target for penile disorders. Expert Opin Ther Targets 10, 445-457.
11. Burnett AL, Kan-Dobrosky N & Miller MG. (2013) Testosterone replacement with 1% testosterone gel and priapism: no definite risk relationship. J Sex Med doi: 10.1111/jsm.12059. [Epub ahead of print]
12. Champion HC, Bivalacqua TJ, Takimoto E, Kass DA & Burnett AL. (2005) Phosphodiesterase-5a dysregulation in penile erectile tissue is a mechanism of priapism. Proc Natl Acad Sci USA 102, 1661-1666.
13. Corona G, Rastrelli G, Monami M, Guay A, Buvat J, Sforza A et al. (2011) Hypogonadism as a risk factor for cardiovascular mortality in men: a meta-analytic study. Eur J Endocrinol 165, 687-701.
14. Dada OA & Nduka EU. (1980) Endocrine function and haemoglobinopathies: relation between the sickle cell gene and circulating plasma levels of testosterone, luteinising hormone (LH) and follicle stimulating hormone (FSH) in adult males. Clin Chim Acta 105, 269-273.
15. Feldman HA, Longcope C, Derby CA, Johannes CB, Araujo AB, Coviello AD et al. (2002) Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts male aging study. J Clin Endocrinol Metab 87, 589-598.
16. Feneley MR & Carruthers M. (2012) Is testosterone treatment good for the prostate? Study of safety during long-term treatment. J Sex Med doi: 10.1111/j.1743-6109.2012.02808.x. [Epub ahead of print]
17. Fowler JE Jr & Whitmore WF Jr. (1982) Considerations for the use of testosterone with systemic chemotherapy in prostatic cancer. Cancer 49, 1373-1377.
18. Jan Z, Pfeifer M & Zorn B. (2012) Reversible testosterone- induced azoospermia in a 45 year old man attending an infertility outpatient clinic. Andologia 44, 823-825.
19. Kato GJ, McGowan V, Machado RF, Little JA, Taylor J, Morris CR et al. (2006) Lactate dehydrogenase as a biomarker of hemolysis-associated nitric oxide resistance, priapism, leg ulceration, pulmonary hypertension, and death in patients with sickle cell disease. Blood 107, 2279-2285.
20. Key LL, Myers MC, Kroovand RL & Kelly WS. (1989) Priapism following testosterone therapy for delayed puberty. Am J Dis Child 143, 1001-1002.
21. Lundh B & Gardner FH. (1970) The haematological response to androgens in sickle cell anaemia. Scand J Haematol 7, 389-397.
22. Mackey MA, Conway AJ & Handelsman DJ. (1995) Tolerability of intramuscular injections of testosterone ester in oil vehicle. Hum Reprod 10, 862-865.
23. Mantadakis E, Cavender JD, Rogers ZR, Ewalt DH & Buchanan GR. (1999) Prevalence of priapism in children and adolescents with sickle cell anemia. J Pediatr Hematol Oncol 21, 518-522.
24. Meusburger SM & Keast JR. (2001) Testosterone and nerve growth factor have distinct but interacting effects on structure and neurotransmitter expression of adult pelvic ganglion cells in vitro. Neuroscience 108, 331-340.
25. Montague DK, Jarow J, Broderick GA, Dmochowski RR, Heaton JP, Lue TF et al. (2003) American urological association guideline on the management of priapism. J Urol 170, 1318-1324.
26. ®) in testosterone deficiency syndrome in Korean: a multicenter prospective study. J Sex Med 7, 2253-2260.
27. Morelli A, Filippi S, Mancina R, Luconi M, Vignozzi L, Marini M et al. (2004) Androgens regulate phosphodiesterase type 5 expression and functional activity in corpora cavernosa. Endocrinology 145, 2253-2263.
28. Morley JE, Charlton E, Patrick P, Kaiser FE, Cadeau P, McCready D et al. (2000) Validation of a screening questionnaire for androgen deficiency in aging males. Metabolism 49, 1239-1242.
29. Morrison BF & Burnett AL. (2012) Stuttering priapism: insights into pathogenesis and management. Curr Urol Rep 13, 268-276.
30. Olambiwonnu NO, Penny R & Frasier SD. (1975) Sexual maturation in subjects with sickle cell anemia: studies of serum gonadotropin concentration, height, weight, and skeletal age. J Pediatr 87, 459-464.
31. Osegbe DN & Akinyanju OO. (1981) Fertility in males with sickle cell disease. Lancet 2, 275-276.
32. Osegbe DN & Akinyanju OO. (1987) Testicular dysfunction in men with sickle cell disease. Postgrad Med J 63, 95-98.
33. Parshad O, Stevens MC, Preece MA, Thomas PW & Serjeant GR. (1994) The mechanism of low testosterone levels in homozygous sickle-cell disease. West Indian Med J 43, 12-14.
34. Pierorazio PM, Bivalacqua TJ & Burnett AL. (2011) Daily phosphodiesterase type 5 inhibitor therapy as rescue for recurrent ischemic priapism after failed androgen ablation. J Androl 32, 371-374.
35. Prasad AS, Schoomaker EB, Ortega J, Brewer GJ, Oberleas D & Oelshlegel FJ Jr. (1975) Zinc deficiency in sickle cell disease. Clin Chem 21, 582-587.
36. Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J & Mishra A. (1997) The International Index of Erectile Function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 49, 822-830.
37. Saad F & Gooren LJ. (2011) The role of testosterone in the etiology and treatment of obesity, the metabolic syndrome, and diabetes mellitus type 2. J Obes 2011, doi: 10.1155/2011/471584
38. Saad F, Grahl AS, Aversa A, Yassin AA, Kadioglu A, Moncada I et al. (2007) Effects of testosterone on erectile function: implications for the therapy of erectile dysfunction. BJU Int 99, 988-992.
39. rd edn (eds GR Serjeant & BE Serjeant), pp. 3-15. Oxford University Press, Oxford.
40. Singhal A, Gabay L & Serjeant GR. (1995) Testosterone deficiency and extreme retardation of puberty in homozygous sickle-cell disease. West Indian Med J 44, 20-23.
41. Slayton W, Kedar A & Schatz D. (1995) Testosterone induced priapism in two adolescents with sickle cell disease. J Pediatr Endocrinol Metab 8, 199-203.
42. Traish A & Kim N. (2005) The physiological role of androgens in penile erection: regulation of corpus cavernosum structure and function. J Sex Med 2, 759-770.
43. Wang C, Harnett M, Dobs A & Swerdloff R. (2010) Pharmacokinetics and safety of long-acting testosterone undecanoate injections in hypogonadal men: an 84 week phase III clinical trial. J Androl 31, 457-465.
44. World Health Organization Quality of Life Group (1998) Development of the world health organization WHOQOL-BREF quality of life assessment. The WHOQOL group. Psychol Med 28, 551-558.
45. Yassin AA & Saad F. (2006) Treatment of sexual dysfunction of hypogonadal patients with long-acting testosterone undecanoate (Nebido). World J Urol 24, 639-644.
46. Zargooshi J. (2000) Priapism as a complication of high dose testosterone therapy in a man with hypogonadism. J Urol 163, 907.
47. Zelissen PM & Stricker BH. (1988) Severe priapism as a complication of testosterone substitution therapy. Am J Med 85, 273-274.
48. Zitzmann M, Mattern A, Hanisch J, Gooren L, Jones H & Maggi M. (2012) IPASS: a study on the tolerability and effectiveness of injectable testosterone undecanoate for the treatment of male hypogonadism in a worldwide sample of 1, 438 men. J Sex Med. Epub.
49. Zvara P, Sioufi R, Schipper HM, Begin LR & Brock GB. (1995) Nitric oxide mediated erectile activity is a testosterone dependent event: a rat erection model. Int J Impot Res 7, 209-219.